EXEL Penghasilan resik perusahaan exelixis.com

Exelixis, Inc. (EXEL) financial results demonstrate attempts to overcome dependence on a single flagship drug through the development of new molecules. The metric value is 0.85. Business stability is supported by a broad oncology portfolio and deals with global players. Synergy with pharma behemoths within joint trials allows Exelixis, Inc. (EXEL) to create more effective targeted therapy methods.

EXEL Exelixis: Penghasilan resik ing interval 04.07.2022 - 30.10.2026

Rincian metrik komprehensif lan analitis Exelixis (EXEL)

- rega saham lan konsensus proyeksi valuasi:

Bagan rega Exelixis Inc.|EXEL - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Exelixis Inc.|EXEL - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Siji Saham Exelixis|EXEL - Aset Bersih Perusahaan|Koefisien Nilai Pasar marang Nilai Buku exelixis.com|EXEL - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Exelixis, Inc.|EXEL - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Exelixis Inc|EXEL - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Exelixis Inc.|EXEL - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Exelixis|Likuiditas kritis exelixis.com

- data bathi bisnis lan rasio investasi:

EXEL - Bathi resik

Pambiji fundamental:Exelixis, Inc.

The profit history of Exelixis, Inc. (EXEL) reflects the commercialization efficiency of its innovative drugs. This indicator measures the net financial result, allowing investors to assess business resilience through the lens of daily totals. The calculation model filters out market noise, revealing the issuer's actual ability to generate cash flow. For Exelixis, Inc. (EXEL), this metric confirms independence from macroeconomic cycles due to stable demand for healthcare. Growth in this metric signals the successful completion of clinical trials.

Pesaing utama